Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients
Reston, VA—A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in ...